|
?:authorAffiliation
|
-
[\'Aerogen Pharma Corp., San Mateo, California, USA.\', \'Division of Respiratory Care, Department of Cardiopulmonary Sciences, Rush University Medical Center, Chicago, Illinois, USA.\', \'CHRU Tours, Médecine Intensive Réanimation, CIC INSERM 1415, CRICS-TriggerSep Research Network, Tours, France.\', \'INSERM, Centre d\'étude des Pathologies Respiratoires, U1100, Université de Tours, Tours, France.\', \'Aerogen Limited, Galway, Ireland.\', \'Department of Medicine, University of California, San Diego, California, USA.\', \'Mechanical Engineering, University of Alberta, Edmonton, Canada.\', \'Adolphe Merkle Institute, University of Fribourg, Fribourg, Switzerland.\', \'Lovelace Biomedical, Albuquerque, New Mexico, USA.\', \'VisionHealth GmbH, Garching Forschungszentrum, Germany.\', \'School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons, Dublin, Ireland.\', \'School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, Ireland.\', \'Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, State University of New York at Stony Brook, Stony Brook, New York, USA.\', \'Vectura GmbH, Gauting, Germany.\', \'Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.\', \'Department of Medicine, Graduate School of Medicine, University of Tennessee Health Science Center, Knoxville, Tennessee, USA.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}